Published in AIDS Weekly, February 9th, 1998
These structures are so important that nearly all retroviral NC have one or two of these structures. Compounds that abolish zinc binding in this region prevent viral replication. Two such compounds, identified as zinc ejectors only after their anti-HIV activities had been detected, already are in clinical trials.
"Our studies provide the basis for an...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.